Boston Scientific Corporation $BSX Shares Bought by Angeles Wealth Management LLC

Angeles Wealth Management LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 14.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,983 shares of the medical equipment provider’s stock after buying an additional 617 shares during the quarter. Angeles Wealth Management LLC’s holdings in Boston Scientific were worth $535,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Invesco Ltd. grew its position in shares of Boston Scientific by 5.3% in the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after purchasing an additional 834,274 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. Amundi grew its position in shares of Boston Scientific by 2.6% in the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock valued at $1,212,408,000 after purchasing an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Boston Scientific by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock valued at $1,139,938,000 after purchasing an additional 460,580 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Robert W. Baird lifted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Truist Financial raised their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, Evercore ISI decreased their price target on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $120.71.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

Shares of BSX stock opened at $99.20 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm’s 50-day moving average is $101.29 and its two-hundred day moving average is $101.74. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a market capitalization of $146.99 billion, a PE ratio of 59.05, a price-to-earnings-growth ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm earned $0.62 earnings per share. Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.